NCT00371254View on ClinicalTrials.gov

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Breast CancerMetastasis
Interventions
DRUG

Dasatinib

Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)

DRUG

Dasatinib

Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)

Trial Locations (10)

10461

Montefiore Medical Center, The Bronx

25198

Local Institution, Lleida

31052

Local Institution, Toulouse

32224

Mayo Clinic Jacksonville, Jacksonville

41100

Local Institution, Modena

75231

Local Institution, Paris

77030

University Of Texas Md Anderson Cancer Ctr, Houston

94143

Ucsf-Comprehensive Cancer Center, San Francisco

02115

Dana-Farber Cancer Inst, Boston

08035

Local Institution, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00371254 - A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer | Biotech Hunter | Biotech Hunter